Ben Tre Pharmaceutical JSC (DBT)

Currency in VND
12,550.0
+50.0(+0.40%)
Closed·

DBT Financial Summary

Key Ratios

P/E Ratio27.71
Price/Book0.9
Debt / Equity206.46%
Return on Equity4.61%
Dividend Yield0.00%
EBITDA65.49B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2012
31/12
2013
31/12
2014
31/12
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2023
31/12
2024
31/12
* In Millions of VND (except for per share items)

Earnings

Latest Release
Apr 29, 2025
EPS / Forecast
129.36 / --
Revenue / Forecast
161.23B / --
EPS Revisions
Last 90 days

FAQ

What were Ben Tre Pharmaceutical JSC's earnings for the latest quarter?

The Ben Tre Pharmaceutical JSC EPS (TTM) is 425.96. Ben Tre Pharmaceutical JSC reported sales of 161,230.72, net income of 2,655.74, and EPS of 129.36 for the latest quarter.

What was Ben Tre Pharmaceutical JSC's net income for the latest quarter?

Ben Tre Pharmaceutical JSC's net income for the latest quarter was 2,655.74.

How did Ben Tre Pharmaceutical JSC's performance compare year-over-year in the latest quarter?

The company's revenue moved from 258,393.55 in the previous quarter to 161,230.72 in the latest quarter, and net income moved from 4,260.14 to 2,655.74 compared to the previous quarter.

What is Ben Tre Pharmaceutical JSC's net profit margin on a TTM basis?

Ben Tre Pharmaceutical JSC's trailing twelve months (TTM) net profit margin is 1.68%.

How does Ben Tre Pharmaceutical JSC's debt to equity ratio compare to industry standards?

Ben Tre Pharmaceutical JSC's total debt-to-equity ratio is 206.46%.

What is Ben Tre Pharmaceutical JSC's return on investment on a TTM basis?

Ben Tre Pharmaceutical JSC's trailing twelve months (TTM) return on investment (ROI) is 4.61%.

Did Ben Tre Pharmaceutical JSC gain or lose cash last quarter?

In the latest quarter, Ben Tre Pharmaceutical JSC's net change in cash was 10,685.80 million.

What were Ben Tre Pharmaceutical JSC's total assets and liabilities in the latest quarter?

As of the latest quarter, Ben Tre Pharmaceutical JSC reported total assets of 979,881.76 million and total liabilities of 662,982.13 million.

How has Ben Tre Pharmaceutical JSC's total revenue grown this year?

Ben Tre Pharmaceutical JSC's total revenue was 258,393.55 in the previous quarter and 161,230.72 in the latest quarter.

What is Ben Tre Pharmaceutical JSC's gross margin on a TTM basis?

Ben Tre Pharmaceutical JSC's trailing twelve months (TTM) gross margin is 41.13%.

What was Ben Tre Pharmaceutical JSC's revenue per share for the latest quarter?

Ben Tre Pharmaceutical JSC's revenue per share for the latest quarter was 29,424.14.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.